

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2008 (11.12.2008)

PCT

(10) International Publication Number
WO 2008/150832 A1

(51) International Patent Classification:
G01N 33/58 (2006.01)

(21) International Application Number:

PCT/US2008/065028

(22) International Filing Date: 29 May 2008 (29.05.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/941,045 31 May 2007 (31.05.2007) US

(71) Applicant (for all designated States except US): **SANOFI-AVENTIS** [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PEPPARD, Jane V.** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US). **MEHDI, Shujaath** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US). **LI,**

Zhuyin [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US). **DUGUID, Mei S.** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(74) Agents: **SZCZEPANIK, Ann Marie** et al.; Sanofi-Aventis U.S. Inc., Route 202-206, P. O. Box 6800, Bridgewater, New Jersey 08807 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: ASSAY METHODS FOR IDENTIFYING AGENTS THAT MODIFY THE ACTIVITY OF NAPE-PLD OR ABH4




Figure 1

(57) Abstract: The present invention provides methods for the detection of agents that modify the activity of the N-acylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD) enzyme or the Alpha/beta-hydrolase-4 (Abh4) enzyme. The disclosed methods are configured in an assay format amenable to high throughput screening applications.

WO 2008/150832 A1



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report*

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

-2-

nitrophenol release from PLD does not involve the N-acyl moiety necessary for NAPE-PLD enzymatic activity (Hagishita et al., Anal. Biochem. 276:161-165, 1999; D'Arrigo et al., Analytica Chimica Acta 304:249-254, 1995). Assays that detect the formation of choline which is the product of many normal PLDs are not useful because NAPE-PLD does not produce choline (Hojjati and Jiang, J. Lipid Res. 47:673-676, 2006). A continuous fluorescence displacement assay for PLD that detects the formation of free fatty acid requires the additional coupling of a phospholipase A enzyme (*i.e.*, an indirect measurement of PLD activity) and employs a substrate lacking the N-acyl moiety (Kinkaid and Wilton, Biochem. Soc. Trans. 25:S595, 1997). Other methodologies utilize techniques such as chromatography, pH changes and membrane charge that are not easily detectable in HTS format (Petersen et al., J. Lipid Res. 41:1532-1538, 2000; Morris et al., Anal. Biochem. 252:1, 1997; Aridor et al., Methods Enzymol. 404:108-115, 2005) Several HTS assays for lipases recently developed do not have the required N-acyl moiety (Schmidt and Bornscheuer, Biomol. Eng. 22:51-56, 2005). Unlike NAPE-PLD, Abh4 is not a zinc dependent enzyme but is a serine hydrolase (Simon and Cravatt, J. Biol. Chem. 281:26465, 2006).

Methods reported for assaying NAPE-PLD activity use radiolabeled NAPE followed by quantifying radiolabeled product released by thin layer chromatography (Okamoto et al, J. Biol. Chem. 279:5298-5304, 2004), zirconium precipitation (Petersen et al., J. Lipid Res. 41:1532-1538, 2000), or liquid chromatography (Fezza et al, Analytical Biochemistry 339 :113-120, 2005).

Fluorescent quenching and fluorescent energy transfer methods are commonly employed in HTS formatted assays. However, fluorescent quenching and fluorescent energy transfer methods or any other HTS-enabling methods have not been applied to NAPE-PLD. We have utilized a fluorescent BODIPY group and a quenching 2, 4-dinitrophenyl (DNP) group (Hendrickson et al., Anal. Biochem. 276:27-35, 1999) to develop a novel assay for NAPE-PLD enabling high throughput screening. The HTS compatible NAPE-PLD fluorescence assay is based on a BODIPY and DNP dual labeled N-acylphosphatidylethanolamine molecule (PED6) as the substrate. As an intact molecule, the fluorescence from the BODIPY moiety is quenched by the DNP

-3-

moiety; upon enzymatic hydrolysis of PED6, the DNP moiety is released from the BODIPY moiety, allowing fluorescence emission from BODIPY (see Figure 2). The fluorescence intensity is proportional to the activity of NAPE-PLD. This new assay increases throughput of the screening, enabling the testing of more compounds in a short time period. Also, this HTS-formatted assay obviates the handling, waste management and disposal issues associated with the use of radioactivity and thin layer chromatography of radiolabeled material.

Abh4 is a member of a family of hydrolases that contain the signature alpha/beta protein fold. Abh4 has been proposed to participate in a pathway for the biosynthesis of the endocannabinoid arachidonlethanolamide (AEA; anandamide) (Simon and Cravatt, J. Biol. Chem. 281:26465, 2006). This pathway has been proposed as an alternative to the pathway that uses the enzyme NAPE-PLD. The assay described by Simon and Cravatt for measuring the enzymatic activity of Abh4 uses a radioactive NAPE substrate, followed by separation by thin layer chromatography of products. Such an assay is cumbersome and clearly not suited to screening compounds with any reasonable throughput. In addition, the use of radioactivity is undesirable for routine assays due to precautionary handling and disposal procedures. The radioactive substrate used by Simon and Cravatt is a NAPE that has no chemical tags, fluorescent or otherwise.

We hypothesized that the NAPE analog PED6, used for the first time successfully by us for measuring NAPE-PLD activity, could be useful for Abh4 as well. We anticipated that Abh4 would cleave the ester bond at the 2-position which is a different bond from that cleaved by NAPE-PLD (see Figure 3), but the end result of an increase in fluorescence upon relief of quenching would be the same. The ester bond at the 1- position may be cleaved as well by Abh4 but will not produce a measurable fluorescence change. The use of the tagged substrate PED6 for the Abh4 enzyme is novel as it is not at all apparent that the enzyme would tolerate the tags in the substrate and hydrolyze PED6 to a measurable extent .

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the hydrolysis of N-acylphosphatidylethanolamine (NAPE) to phosphatidic acid and anandamide by the enzyme N-acylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD).

Figure 2 shows a schematic representation of an intact molecule of PED6 comprising the fluorescence group of the BODIPY moiety and the quenching group of the DNP moiety. Upon enzymatic hydrolysis by NAPE-PLD, the DNP moiety is released from the BODIPY moiety, allowing fluorescence emission from BODIPY.

Figure 3 shows possible positions of donor and acceptor (or quencher) moieties of any two suitably situated fluorescent molecules, for instance, BODIPY and DNP. Cleavage sites of NAPE-PLD and Abh4 are noted.

Figure 4 shows the effects Triton X-100 and lipids used to prepare PED6 substrate on the signal-to-background ratio of BODIPY fluorescence measuring NAPE-PLD activity. Final Triton X-100 concentration was 0.0125 %. Chloroform was used to dissolve the substrate.

Figure 5 shows the effects of Triton X-100 when ethyl acetate is used to dissolve the PED6 substrate on the signal-to-background ratio of BODIPY fluorescence measuring NAPE-PLD activity.

Figure 6 shows a PED6 substrate titration curve (CPS=counts per second).

Figure 7 shows a NAPE-PLD enzyme titration curve (CPS=counts per second).

Figure 8 shows the K_m determination for NAPE-PLD.

Figure 9 shows a DMSO sensitivity curve for the NAPE-PLD assay.

Figure 10 shows representative IC_{50} curves.

-5-

Figure 11 shows the nucleotide sequence (SEQ ID NO:1) used to express NAPE-PLD with a C-terminal 6x His tag; the NAPE-PLD protein with C-terminal His tag that was expressed and purified was found to be truncated at the N-terminus (SEQ ID NO. 3) compared to the sequence of full-length NAPE-PLD (SEQ ID NO. 2).

Figure 12 shows the expressed amino acid sequence of Abh4 with C-terminal His tag (SEQ ID NO: 5).

Figure 13 shows representative traces following the fluorescence emission resulting from hydrolysis of PED6 by Abh4 over time (emission wavelength 520nm). Time is in seconds (secs), RFU is relative fluorescent units in milli-flourescent units per minute (mRFU/min). A1 (open circle) represents substrate control alone (slope = 17335 mRFU/min), A2 (open square) represents lysate from cells transfected with vector containing Abh4 (slope = 849272 mRFU/min), A3 (open triangle) represents lysate from untransfected cells (slope = 41622 mRFU/min).

DETAILED DESCRIPTION OF THE INVENTION

All publications cited herein are hereby incorporated by reference. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains.

The terminology used in this specification and the appended claims is for the purpose of describing particular embodiments only and use in the specification is not intended to be limiting of the invention. The singular forms of a word are intended to include the plural forms unless the context clearly indicates otherwise. For example, the singular forms of "a", "an" and "the" are intended to include the plural forms as well. Further, reference to an agent may include a mixture of two or more agents. Thus, the term "an agent" includes a plurality of agents, including mixtures and/or

-6-

enantiomers thereof. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the context clearly dictates otherwise. It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, steps, elements, and/or
5 components, but do not preclude the presence or addition of one or more other features, steps, elements, components, and/or groups thereof.

Furthermore, in accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques
10 within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D. N. Glover ed. 1985); *Oligonucleotide Synthesis* (M. J. Gait ed. 1984); *Nucleic
15 Acid Hybridization* [B. D. Hames & S. J. Higgins eds. (1985)]; *Transcription And Translation* [B. D. Hames & S. J. Higgins, eds. (1984)]; *Animal Cell Culture* [R. I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F. M. Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

20
An embodiment of the invention is a method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising: (a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles; (b) adding an agent to at least one receptacle in the array of receptacles; (c) adding a substrate
25 to at least one receptacle in the array of receptacles wherein the substrate comprises a donor moiety and a quencher moiety wherein intramolecular proximity of the donor moiety and the quencher moiety results in a quenched detectable signal; (d) incubating the agent, the NAPE-PLD or Abh4 and the substrate in the array of receptacles for a predetermined period of time; (e) measuring the amount of
30 detectable signal from the donor moiety following removal of the quencher moiety from the substrate by NAPE-PLD or Abh4 in the array of receptacles; and (f) comparing the amount of detectable signal in a first receptacle comprising the agent, the substrate and the NAPE-PLD or Abh4 to the amount of detectable signal in a

-7-

second receptacle comprising the substrate and the NAPE-PLD or Abh4 thereby identifying said agent as a modifying agent when the difference exceeds a predetermined threshold.

5 A further embodiment of the invention is a method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising: (a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles; (b) adding an agent to at least one receptacle in the array of receptacles; (c) adding a substrate to at least one receptacle in the array of receptacles wherein the substrate comprises
10 a donor moiety and a quencher moiety wherein intramolecular proximity of the donor moiety and the quencher moiety results in a quenched detectable signal; (d) measuring the amount of detectable signal from the donor moiety following removal of the quencher moiety from the substrate by NAPE-PLD or Abh4 in the array of receptacles at a first time point; (e) incubating the agent, the NAPE-PLD or Abh4 and
15 the substrate in the array of receptacles for a predetermined period of time; (f) measuring the amount of detectable signal from the donor moiety following removal of the quencher moiety from the substrate by NAPE-PLD or Abh4 in the array of receptacles at a second time point; and (g) comparing the amount of detectable signal at the first time point to the amount of detectable signal at the second time
20 point, thereby identifying said agent as a modifying agent when the difference exceeds a predetermined threshold.

"Predetermined" indicates the period of time or the threshold is established in advance of employing the method of the invention. The period of time or threshold
25 may be selected arbitrarily or empirically. A non-limiting example is to perform a time course and then to select a time to measure the detectable signal based on the results of the time course. "Period of time" can be any unit of time; non-limiting examples include seconds, minutes or hours. "Threshold" refers to the amount of detectable signal required to indicate a response.

30

An embodiment of the invention utilizes a detectable signal. The skilled artisan can readily appreciate the vast number of detectable signals that may be employed by the instant invention. Non-limiting examples include fluorochromes, chromophores,

enzymes, linker moieties, biotin, electron donors, electron acceptors, dyes, metals, and radionuclides.

An embodiment of the invention uses a donor moiety and a quencher moiety.
5 Non-limiting examples include BODIPY and DNP, Rhodamine and DNP, Cy dye and DNP, Alexa and QSY dyes, BODIPY and DNP. The skilled artisan can readily identify other appropriate combinations using different donor and quencher moieties having the appropriate properties such that they may be utilized by the instant invention.

10 The instant invention is amendable to the utilization of many technologies to generate a detectable signal . A non-limiting example is the use of fluorescence resonance energy transfer (more commonly referred to as FRET). Fluorescence resonance energy transfer is a process whereby the transfer of energy occurs from an excited state fluorophore to a second chromophore in close proximity. For
15 instance, fluorescence resonance energy transfer involves a donor fluorophore in an excited electronic state, which may transfer its excitation energy to a nearby acceptor chromophore through long-range dipole-dipole interactions. Resonance energy transfer can be thought of as coupled oscillators, such as a pair of tuning forks vibrating at the same frequency. Thus, depending on the donor and acceptor moieties
20 used, the skilled artisan can measure the detectable signal resulting from the intramolecular interaction of the donor-acceptor pair and the detectable signal from the donor moiety and the acceptor moiety or both following separation or disruption of the intramolecular interaction. Non limiting examples of donor-acceptor pairs include cyan fluorescent protein-yellow fluorescent protein pair, green fluorescent protein-
25 blue fluorescent protein pairs, europium and allophycocyanin, cyan fluorescent protein/yellow fluorescent protein, green fluorescent protein/blue fluorescent protein, and combination of different Cy dyes, different BODIPY dyes or different Alexa dyes with appropriate excitation and emission wavelengths, Texas Red and Fluorescein, BODIPY and fluorescein, Rhodamine and Fluorescein, combination of different
30 BODIPY dyes with appropriate fluorescent properties, combination of different Cy dyes with appropriate fluorescent properties, and europium chelates or other lanthanide chelates and APC, XL665 or other modified APCs. The skilled artisan can readily appreciate that Cy dye is a general name for many dyes with similar structure

but different fluorescent properties. Likewise, BODIPY and Alexa dyes represent a class of dyes that have similar structures and different fluorescent properties. Thus, in theory, a multitude of combinations would be appropriate for FRET. A nonlimiting example is BODIPY 480 with Cy dye 520.

5

Thus, an embodiment of the invention is a method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising: (a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles; (b) adding an agent to at least one receptacle in the array of receptacles; (c) adding a substrate
10 to at least one receptacle in the array of receptacles wherein the substrate comprises a donor moiety and an acceptor moiety; (d) incubating the agent, the NAPE-PLD or Abh4 and the substrate for a predetermined period of time; (e) measuring the amount of detectable signal wherein the detectable signal measured is selected from the group consisting of the donor moiety, the acceptor moiety, the ratio of donor moiety to
15 acceptor moiety and the donor-acceptor moiety complex; and (f) comparing the amount of detectable signal in a first receptacle comprising the agent, the substrate and the NAPE-PLD or Abh4 to the amount of detectable signal in a second receptacle comprising the substrate and the NAPE-PLD or Abh4 thereby identifying said agent as a modifying agent when the difference exceeds a predetermined
20 threshold.

A further embodiment of the invention is a method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising: (a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles; (b) adding
25 an agent to at least one receptacle in the array of receptacles; (c) adding a substrate to at least one receptacle in the array of receptacles wherein the substrate comprises a donor moiety and an acceptor moiety; (d) measuring the amount of detectable signal at a first time point wherein the detectable signal measured is selected from the group consisting of the donor moiety, the acceptor moiety, the ratio of donor
30 moiety to acceptor moiety and the donor-acceptor moiety complex; (e) incubating the agent, the NAPE-PLD or Abh4 and the substrate for a predetermined period of time; (f) measuring the amount of detectable signal at a second time point wherein the detectable signal measured is selected from the group consisting of the donor moiety,

-10-

the acceptor moiety, the ratio of donor moiety to acceptor moiety and the donor-acceptor moiety complex; and (g) comparing the amount of detectable signal at the first time point to the amount of detectable signal at the second time point thereby identifying said agent as a modifying agent when the difference exceeds a
5 predetermined threshold.

Since the principle of the instant invention is based on the transfer of energy within the substrate molecule from an energy donor moiety to an energy acceptor moiety. At the broadest scope, the assay is functional when any two suitably situated
10 moieties, the donor and the acceptor (or the quencher), are linked by the substrate molecule. As a non-limiting example, a donor is placed on one of the three fatty acid chains (*e.g.*, chain 1 or 2) of the NAPE substrate, and an energy acceptor (or quencher) is placed at a separate site which is still close enough for energy transfer to occur (*e.g.*, chain 3, see Figure 3). Before the substrate is hydrolyzed, the donor
15 and acceptor (or quencher) are in close proximity, and detectable signal from the donor is quenched by the acceptor (or quencher). Upon substrate hydrolysis, the donor and acceptor (or quencher) are separated, resulting in release of the detectable signal, for instance, fluorescence from the donor, that serves as a readout for detecting the enzyme activity. As an alternative example, upon substrate
20 hydrolysis and separation of donor and acceptor, fluorescence from donor can be detected and fluorescence from the acceptor can be detected, wherein one or both of the donor and acceptor signals can be measured or a ratio of donor to acceptor can be measured.

25 The following are non-limiting examples of combinations of donor-acceptor locations: chain 1 and 3, chain 2 and 3, chain 3 and 1, or chain 3 and 2 (Figure 3). One skilled in the art will appreciate that the hydrocarbon chains of chain 1 and 2 can be varied. Chain 3 may also be varied but the N-acyl moiety should be maintained. The fluorescence probes can be located at any position of the chains as long as the
30 modification does not interfere with the activity of the NAPE-PLD enzyme. The fluorescent donor and acceptor pairs have to be compatible in that, when excited by one wavelength the donor emits light of an appropriate wavelength to be accepted or quenched by the opposing fluorophore. There are several combinations of fluorescent

-11-

donor-acceptor pairs. As illustration, non-limiting examples of usable combinations include: cyan fluorescent protein-yellow fluorescent protein pair, green fluorescent protein-blue fluorescent protein pairs, europium and allophycocyanin, cyan fluorescent protein/yellow fluorescent protein, green fluorescent protein/blue fluorescent protein, and combination of different Cy dyes, different BODIPY dyes or different Alexa dyes with appropriate excitation and emission wavelengths, BODIPY and DNP, Rhodamine and DNP, Cy dye and DNP, Alexa and QSY dyes, BODIPY and DNP, Texas Red and Fluorescein, BODIPY and fluorescein, Rhodamine and Fluorescein, combination of different BODIPY dyes with appropriate fluorescent properties, combination of different Cy dyes with appropriate fluorescent properties, and europium chelates or other lanthanide chelates and APC, XL665 or other modified APCs.

The skilled artisan can readily appreciate that the order of adding NAPE-PLD or Abh4, agent and substrate can be performed arbitrarily or may be performed together. A non-limiting example is to prepare the NAPE-PLD or Abh4, substrate and agent in one mixture and to add the mixture in one step. Another non-limiting example is to add substrate first, then agent and then NAPE-PLD or Abh4. Any order of addition may be followed. A further embodiment is that an incubation for a predetermined period of time of any one or more of either NAPE-PLD or Abh4, agent or substrate may be added between steps a, b or c. Refinements such as adding the substrate, agent or NAPE-PLD or Abh4 in a single step or in a different order are well within the knowledge and capability of the skilled artisan and are considered embodiments of the invention.

An embodiment of the invention utilizes a substrate. The substrate may be any material or substance that NAPE-PLD or Abh4 may act upon. A non-limiting example is PED6.

An embodiment of the invention utilizes the enzyme NAPE-PLD comprising full-length human NAPE-PLD. NAPE-PLD from other species may also be used. NAPE-PLD may be expressed to comprise other proteins as well, for example, HIS tags that are useful for protein isolation. Further, truncated versions of the NAPE-PLD

-12-

enzyme may be used. A non-limiting example is SEQ ID NO. 3. If truncated, the truncation may not interfere with the active site. Any truncation may be used provided that the active site is still contained and intact within the truncated protein.

5 An embodiment of the invention utilizes the enzyme Abh4 comprising full-length human Abh4. A non-limiting example is SEQ ID NO. 5. Abh4 from other species may also be used. Abh4 may be expressed to comprise other proteins as well, for example, HIS tags that are useful for protein isolation. Further, truncated versions of the Abh4 enzyme may be used. If truncated, the truncation may not
10 interfere with the active site. Any truncation may be used provided that the active site is still contained and intact within the truncated protein.

The present invention provides methods for identifying (*e.g.*, screening, detecting, characterizing, analyzing and quantifying) agents that modify the activity of
15 NAPE-PLD or Abh4. The term "agent", "test agent", "test compound", "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, either naturally occurring or synthetic, *e.g.*, protein, oligopeptide (*e.g.*, from about 5 to about 25 amino acids in length, preferably from about 10 to 20 or 12 to 18 amino acids in length, preferably 12, 15, or 18 amino acids in length), small organic
20 molecule, polysaccharide, lipid (*e.g.*, a sphingolipid), fatty acid, polynucleotide, oligonucleotide, etc., which is employed in the assays of the invention and assayed for its ability to modulate the activity of NAPE-PLD or Abh4. There are no particular restrictions as to the compound that can be assayed. Examples include single agents or libraries of small, medium or high molecular weight chemical molecules,
25 purified proteins, expression products of gene libraries, synthetic peptide libraries, cell extracts and culture supernatants. An agent encompasses any combination of different agents.

An agent may include at least one or more soluble or insoluble factors, cell
30 matrix components, conditioned media, cell extracts, tissue extracts, explants, pH modifiers, gasses, osmotic pressure modifiers, ionic strength modifiers, viruses, DNA, RNA or gene fragments. An agent can be in the form of a library of test agents, such as a combinatorial or randomized library that provides a sufficient range of diversity or

-13-

conversely is limited to similar structures or features. Agents can be optionally linked to a fusion partner, *e.g.*, targeting compounds, rescue compounds, dimerization compounds, stabilizing compounds, addressable compounds, and other functional moieties. Conventionally, new chemical entities with useful properties are generated by identifying a test agent (called a "lead compound" or a "lead") with some desirable property or activity, *e.g.*, inhibiting activity or modulating activity. The lead compound is then used as a scaffold to create variants of the lead compound, and further evaluate the property and activity of those variant compounds.

10 An agent may include treatment conditions and manipulation of external and internal conditions or environment. A non-limiting example of such an agent includes ultraviolet light.

 An embodiment of the invention is a method for identifying an agent that modifies the activity of NAPE-PLD or Abh4. The term "modifies" encompasses any change in activity or specificity of NAPE-PLD or Abh4. Thus, the term "modifies" may refer to an agent that is an inhibitor, inducer or modulator of NAPE-PLD activity or Abh4 activity.

20 The term "inhibitor" encompasses any drug, chemical, protein or protein fragment capable of blocking, interrupting or preventing the activity or specificity of NAPE-PLD or Abh4. Further, an inhibitor may be, *e.g.*, a molecular chaperone, antibody or inhibitory RNA (RNAi) that blocks expression of cellular proteins thereby inhibiting pathways directly or indirectly affecting NAPE-PLD or Abh4. "Block", "blocks" or "blocking" need not be absolute but any measurable inhibition is an indication that blocking has occurred. An "inhibitor" may be the manipulation of culturing conditions such as oxygen augmentation or deprivation or changing media components in such a manner as to block, interrupt or prevent a cellular response thereby preventing or interrupting, or blocking the activity or specificity of NAPE-PLD or Abh4.

30 The term "inducer" encompasses any drug, chemical, protein or protein fragment capable of initiating, stimulating or enhancing the activity or specificity of

-14-

NAPE-PLD or Abh4. Further, an inducer may be a molecular chaperone, antibody or inhibitory RNA (RNAi) that blocks expression of cellular proteins thereby removing inhibition or directly initiating or stimulating a cellular response, activity or pathway. An "inducer" may be the manipulation of culturing conditions such as oxygen
5 augmentation or deprivation or changing media components in such a manner as to block, interrupt or prevent a cellular response ultimately initiating, stimulating or enhancing the activity or specificity of NAPE-PLD or Abh4.

The term "modulator" encompasses any drug, chemical, protein or protein
10 fragment capable of adjusting the intensity, proportion or the characteristics of the activity or specificity of NAPE-PLD or Abh4 or of a cellular response, activity or pathway involved in the activity or specificity of NAPE-PLD or Abh4. Further, a modulator may be a molecular chaperone, antibody or inhibitory RNA (RNAi) that blocks expression of cellular proteins thereby removing inhibition or inducing a
15 cellular response, activity or pathway that ultimately affects the activity or specificity of NAPE-PLD or Abh4. A "modulator" may be the manipulation of culturing conditions such as oxygen augmentation or deprivation or changing media components in such a manner as to adjust the intensity, proportion or the characteristics of a cellular response that may affect the activity or specificity of NAPE-PLD or Abh4.

20 In a further embodiment of the invention, a modulator may be used in conjunction with an inducer such that a modulator of an inducer makes the inducer more potent (*e.g.*, resulting in an enhanced NAPE-PLD or Abh4 activity) or the inducer less potent (*e.g.*, resulting in a reduced NAPE-PLD or Abh4 activity). A
25 modulator of an inhibitor makes the inhibitor less potent (*e.g.*, enhanced NAPE-PLD or Abh4 activity) or the inhibitor more potent (*e.g.*, reduced NAPE-PLD or Abh4 activity).

Inhibitors, inducers or modulators can also be utilized to mimic pathways or
30 aspects of disease states. As a non-limiting illustrative example, an embodiment of the invention would be to identify an agent that modifies the activity of NAPE-PLD or Abh4 in the presence of an NAPE-PLD or Abh4 inhibitor, inducer or modulator that mimics aspects of a psychological disorder, diabetes or obesity. Thus, an

-15-

embodiment of the invention encompasses a screening method for identifying a test agent that may ameliorate a disease state where NAPE-PLD or Abh4 activity or specificity is thought to be affected.

5 Another embodiment of the invention is the use of more than one inducer, inhibitor or modulator. Using more than one inducer, inhibitor or modulator could, but is not limited to, having additive effects, counter effects, synergistic effects or affecting multiple pathways.

10 An embodiment of the invention is a method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method further comprising a control. A control is a term of art well understood by skilled artisans. An appropriate control may be dependent on the assay parameters utilized or the experimental question under investigation. A control may be a particular set of assay conditions or the
15 addition or elimination of a particular compound to the culture medium. A control may be considered a positive control in that the assay conditions or control compound added brings about the anticipated response. For example, if the agent under investigation is expected to inhibit NAPE-PLD or Abh4, a positive control would be a compound or agent known to inhibit NAPE-PLD or Abh4. A control may also be a
20 negative control. A negative control may be a particular set of assay conditions or the addition or elimination of a particular compound or agent to the culture medium that would bring about the anticipated response. For example, if the agent under investigation is expected to inhibit NAPE-PLD or Abh4, then a negative control would be expected to not to inhibit NAPE-PLD or Abh4. A control may be a "vehicle" control.
25 For example, if the test agent is dissolved in DMSO then the vehicle control would be DMSO without test agent. A control may simply be the use of historical data.

 An embodiment of the invention is a method wherein the NAPE-PLD or Abh4
is provided by culturing in the receptacles a prokaryotic or eukaryotic cell that is
30 transiently or stably transfected to express the NAPE-PLD or Abh4. Thus, a further embodiment of the invention is to use cells transiently or stably transformed to express or overexpress NAPE-PLD or Abh4. Expression can be induced or constitutive. Agents can be tested for their ability to modulate NAPE-PLD or Abh4

-16-

activity by adding the agent to receptacles comprising cultured cells transiently or stably transformed to express or overexpress NAPE-PLD or Abh4.

A recombinant expression vector of the invention comprises a nucleic acid molecule in a form suitable for expression of the nucleic acid in a host cell. Thus, a recombinant expression vector of the present invention can include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operably linked to the nucleic acid to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology Vol. 185*, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of the nucleotide sequence in many types of host cells (e.g., tissue specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to produce proteins or peptides encoded by nucleic acids as described herein.

The term "overexpression" as used herein, refers to the expression of a polypeptide, e.g., a molecule that may be involved in apoptosis or cell survival mechanisms, by a cell, at a level that is greater than the normal level of expression of the polypeptide in a cell that normally expresses the polypeptide or in a cell that does not normally express the polypeptide. For example, expression of the polypeptide may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more as compared to expression of the polypeptide in a wild-type, ground state or uninduced cell that normally expresses the polypeptide. Mutants, variants, or analogs of the polypeptide of interest may be overexpressed.

-17-

As used herein, the term "transient" expression refers to expression of exogenous nucleic acid molecule(s) which are separate from the chromosomes of the cell. Transient expression generally reaches its maximum 2-3 days after introduction of the exogenous nucleic acid and subsequently declines.

As used here, the term "stable" expression refers to expression of exogenous nucleic acid molecule(s) that are part of the chromosomes of the cell. In general, vectors for stable expression of genes include one or more selection markers.

Cell culturing techniques for transformed, non-transformed, primary culture and biological samples are well known in the art. Biological samples or cultured cells can be stored until required for use. The media used for culturing can be specifically designed or purchased from commercial sources.

An embodiment of the invention uses cell lines that are commercially available. For example, cells that can be used are available from the American Tissue Culture Company or other sources. Cells may be prokaryotic or eukaryotic. The invention is not limited by the type of cells used. Primary cultures may also be utilized. Non-differentiated cells may be subjected to various agents to cause the cells to differentiate into a particular phenotype. For example, progenitor cells induced to differentiate into oligodendrocytes would be an embodiment of the invention. The particular cell type used may be selected by markers specifically expressed by the desired cell type, or alternatively, by the loss of a particular marker(s). Cells can be separated or sorted by methods such as flow cytometry that are commonly used by skilled artisans.

An embodiment of the invention uses a homogeneous cell population. An alternative embodiment of the invention uses a heterogeneous cell population. The cells can be of any type and in any proportion to complete the assay of the invention.

Cells may be obtained from a biological sample. A biological sample may include, but is not limited to, tissue or fluids, sections of tissues such as biopsy and

-18-

autopsy samples, and frozen sections taken for histologic purposes. Such samples include blood, sputum, tissue, cultured cells, *e.g.*, primary cultures, explants, and transformed cells, stool, urine, etc. A biological sample can be obtained from a eukaryotic organism, including from mammals such as a primate, *e.g.*, chimpanzee, macaque or human, cow, dog, cat, a rodent, *e.g.*, guinea pig, rat, mouse, rabbit, or a bird, reptile, or fish.

An embodiment of the invention is use in high throughput screening (HTS) methods. HTS is the automated, simultaneous testing of thousands of distinct chemical compounds in assays designed to model biological mechanisms or aspects of disease pathologies. More than one compound, *e.g.*, a plurality of compounds, can be tested simultaneously, *e.g.*, in one batch. In one embodiment, the term HTS screening method refers to assays which test the ability of one compound or a plurality of compounds to influence the readout of choice.

An embodiment of the invention utilizes robotic or workstation device. Liquid handling systems, analytical equipment such as fluorescence readers or scintillation counters and robotics for cell culture and sample manipulation are well known in the art. Mechanical systems such as robotic arms or "cherry-picking" devices are available to the skilled artisan. Commercial plate readers are available to analyze, *e.g.*, conventional 96-well or 384-well plates. Single sample, multiple sample or plate sample readers are available that analyze predetermined wells and generate raw data reports. The raw data can be transformed and presented in a variety of ways.

An embodiment of the invention comprises an array of receptacles that can receive cells and other materials such as culture media. An array of receptacles can be any number of receptacles from at least one or more than one receptacle suitable for holding cells within the scope of the invention. Examples include but are not limited to flasks, culture dishes, tubes such as 1.5 ml tubes, 12 well plates, 96 well plates, 384 well plates, 1536 well plates and miniaturized microtiter plates with perhaps 4000 receptacles (U.S. Patent Application 20050255580). The array of receptacles may be amendable to the addition of a protective covering thus preventing against entry of contaminants or evaporation of contents.

A further characteristic of the receptacles is that the receptacle may allow for analysis, non-limiting examples include, spectrophotometric analysis, scintillation counting and fluorescence measurements. However, this is not a limitation to
5 receptacles that can be used within the scope of the invention given that samples can be transferred to a suitable container amenable to further analysis. A non limiting example is to modify the method such that the method further comprises providing a second array of receptacles wherein samples from the first array of receptacles is transferred to the second array of receptacles.

10

An embodiment of the invention is an assay system for identifying an agent that modifies the activity of NAPE-PLD or Abh4, the assay system comprising: (a) an array of receptacles; (b) NAPE-PLD or Abh4; (c) a substrate comprising a donor moiety and a quencher moiety wherein the donor moiety is capable of detection; and
15 (d) at least one component wherein the component is selected from the group consisting of the agent(s), an inducer(s), an inhibitor, a modulator(s), a modulator(s) of the inducer(s), a modulator(s) of the inhibitor(s) and control(s).

20

Another embodiment of the invention is an assay system for identifying an agent that modifies the activity of NAPE-PLD or Abh4, the assay system comprising:
(a) an array of receptacles; (b) NAPE-PLD or Abh4; (c) a substrate comprising a donor moiety and an acceptor moiety wherein the donor moiety or the acceptor
acceptor moiety or both are capable of detection; and (d) at least one component
25 wherein the component is selected from the group consisting of the agent(s), an inducer(s), an inhibitor, a modulator(s), a modulator(s) of the inducer(s), a modulator(s) of the inhibitor(s) and control(s).

30

An embodiment of the invention is a component that modifies the activity or specificity of NAPE-PLD or Abh4. The component is selected from the group consisting of a control, an agent, an inducer, an inhibitor, a modulator, a modulator of the inducer and a modulator of the inhibitor. The assay system can have more than
one component.

-20-

A further embodiment of the invention is a kit comprising at least one element of the assay system and instructions for use. Thus, the components of the assay system may be provided separately or may be provided together such as in a kit. Components of the assay system may be prepared and included in a kit according to
5 methods that maximize the stability of the individual components. Such methods are familiar to those persons skilled in the art. For example, cells of the assay system may be provided as a suspension or lyophilized. Additional components of the system may also be included such as buffers, containers for mixing the assay components such as microtiter plates or test tubes. The assay system can be
10 provided in the form of a kit that includes instructions for performing the assay and instructions for data handling and interpretation.

An embodiment of the invention is a pharmaceutical composition for the modulation of NAPE-PLD or Abh4 comprising a therapeutically effective amount of an
15 agent identified by the methods of the invention and a pharmaceutically acceptable carrier. The term "therapeutically effective amount" refers to an amount of an agent effective to treat a disease or disorder in a subject or mammal. As a non-limiting example, in the case of obesity, the therapeutically effective amount of the drug may reduce the body weight. The pharmaceutical compositions of the present invention
20 can be used in combination with other therapeutic agents. For example, in the treatment of obesity, the pharmaceutical composition may be given in combination with other appetite suppressants.

The invention is further described in the following examples, which do not limit
25 the scope of the invention described in the claims. While the invention has been described and exemplified in sufficient detail for those skilled in this art to produce and use it, various alternatives, modifications, and improvements should be apparent without departing from the spirit and scope of the invention. One skilled in the art readily appreciates that the present invention is well adapted to carry out the
30 objective and obtain the ends and advantages mentioned, as well as those inherent therein. The examples that follow are descriptions of embodiments and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed

-21-

within the spirit of the invention and are defined by the scope of the claims. Varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

5 The invention illustratively described herein may be practiced in the absence of any element or elements, limitation or limitations, which are not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or
10 portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by embodiments and optional features, modification and variation of the concepts herein disclosed may be made by those skilled in the art, and that such modifications and variations are considered to
15 be within the scope of this invention as defined by the appended claims.

Example 1

20 PREPARATION OF NAPE-PLD ENZYME:

 NAPE-PLD has been expressed in E.coli and mammalian cells. Mammalian expression systems were not a good choice for because of the relatively low activity of NAPE-PLD and the large quantity of protein needed for high throughput screening.
25 In order to obtain large amount of protein to support HTS, we tested the expression of NAPE-PLD in E.coli and baculovirus/insect cell systems. The NAPE-PLD expressed in E.coli has lower solubility, lower specific activity, and lower expression level than the protein expressed in baculovirus/insect cells. So, we selected the baculovirus/insect cells as the expression system for supporting HTS. The pDEST8.1
30 vector (Invitrogen) was used to express NAPE-PLD with a C-terminal 6x His tag (SEQ ID NO. 1) in insect cells. This expression system made it possible to generate a large quantity of NAPE-PLD with high purity through metal chelating chromatography.

-22-

The sequence of NAPE-PLD has been previously described (SEQ ID NO. 2). The protein with C-terminal His tag (MW 49 kDa) was expressed and purified in soluble, active form from insect cells in the presence of Triton X-100. The expressed enzyme was found to be truncated at the N-terminus by 46 amino acids (SEQ ID NO. 3).

Example 2

GENERAL ASSAY PARAMETERS:

General assay conditions use the following final concentrations of the following material: NAPE-PLD at 14 nM, PED6 (substrate) at 10 μ M, test compounds at 10 μ M, DMSO at 1 %. PED6 is purchased (see Table 1) as a lyophilized powder and stored at -20 °C. A fresh substrate solution should be prepared daily. 1 mg of PED6 is dissolved in 0.88 ml of ethyl acetate and diluted into 43.12 ml assay buffer to make a 20 μ M working solution. PED6 must be kept out of direct light, as it is light sensitive.

Table 1:

Materials	Supplier	Catalog Number	Function
Black 384 square well, polystyrene non-binding surface assay plates	Costar	3654	Assay Plate
LJL Acquest	Molecular Device		Assay Plate Reader
CyBi-Well Automated CyBi-CyBi-Well Automated Workstation	Cy-Bio	Serial # 3191-3-3122	Compound addition
FLEXDROP 384 Automatic Dispenser	Perkin Elmer	Model # AFELV40	Bulk reagents dispenser
PED6	Invitrogen	D23739	Substrate
Triton X-100, hydrogenated 10% Solution	CalBiochem	648464	Detergent

Test compounds are diluted in an appropriate buffer. A non-limiting example is 50 mM Tris-HCl, pH 8.0, the buffer may contain DMSO, for instance, 10% DMSO. Assay buffer was 50 mM Tris-HCl, pH 8.0, 0.05% Triton X-100 and stop solution is 0.4 M HCl, 0.05% Triton X-100.

-23-

Order of addition of reagents and equipment used:

- 1) Dilute enzyme (NAPE-PLD, 22 μ M) to 28 nM in assay buffer.
- 2) Prepare substrate (20 μ M in assay buffer).
- 5 3) Add 10 μ l NAPE-PLD to assay plate using FLEXDROP.
- 4) Add 2 μ l compound (from compound plate) to appropriate wells of assay plate using Cy-Bio.
- 5) Incubate plates, covered, at room temperature for 30 minutes (compound preincubation).
- 10 6) Add 10 μ l PED6 to assay plate using FLEXDROP.
- 7) Incubate plates, covered, at room temperature for 30 minutes (enzyme reaction)
- 8) Terminate the reaction by adding 20 μ l of stop solution, using FLEXDROP
- 9) Read on LJL Acquest. Excitation filter, 485 nM; emission filter, 530 nM.

15

Example 3

OPTIMIZATION OF SUBSTRATE (PED6) SOLVENT:

Since PED6 and other potential substrates of NAPE-PLD are lipids, they are
 20 extremely hydrophobic. Therefore, it is reasonable to dissolve the substrate in
 chloroform before adding aqueous assay buffer. We added 0 – 0.05% of Triton X-100
 in order to further increase the solubility of PED6 in aqueous solution. Further, high
 concentration of Triton X-100 was also reported to increase the activity of NAPE-PLD
 (up to 0.2%) (Petersen and Hansen, FEBS Lett. 455:41-44, 1999). Under these
 25 substrate solvent conditions, the assay did not work (see Table 2).

Table 2. NAPE-PLD Substrate Assay Conditions

Condition	Organic Solvent Used to Initially Dissolve PED6	Final Detergent Concentration in Assay Buffer	Lipids Used to Aid PED6 Solubility	NAPE-PLD Activity
1	Chloroform used to dissolve PED6 initially, then dried down before adding aqueous	0 - 0.05% Triton X-100	No	No
2	Chloroform	none	PI/PC ratio from	No

-24-

			1:1 to 3:1	
3	Chloroform	0 - 0.05% Triton X-100	PI/PC ratio from 1:1 to 3:1	No
4	Ethyl Acetate*	0 - 0.015% Triton X-100	No	No
5	Ethyl Acetate *	> 0.015 - 0.1% Triton X-100	No	Yes
6	Ethyl Acetate	>0.1% Triton X-100	No	No
*(final concentration in assay buffer 1%) PC=egg yolk phosphatidylcholine, PI=soybean phosphatidylinositol Total PI + PC = 6 mg/ml				

Further research into the problem of how to properly prepare the substrate led us to investigate the assay conditions for other PLDs. One paper used hydrophobic lipid substrates of PLDs that were dissolved in chloroform and were then mixed with a phosphatidylinositol/phosphatidylcholine (PI/PC) blend dissolved in chloroform (Petry et al., J. Lipid Res. 46:603-614, 2005). The final mixture was then dried. To resuspend the mixture in aqueous buffer, ultrasonic treatment was needed. Following this procedure, the assay started to provide a detectable signal, but the signal to background ratio was low. Adding Triton X-100 to the aqueous assay buffer increased the signal to background ratio, but also increased the assay noise (Figure 4). Such a noisy assay was not suitable for high throughput screening.

There are three ways to increase the solubility of hydrophobic lipid substrates in aqueous buffers: organic solvent (like chloroform), lipids (like PI and PC), or detergents (like Triton X-100). Since the organic solvent chloroform used in the initial dissolution ultimately damages the protein, we had to dry off the chloroform before adding aqueous buffer. We hypothesized that if we used a more "protein friendly" organic solvent, such as ethyl acetate, it could remain in the aqueous assay buffer without damaging the protein and help to increase the solubility of the hydrophobic lipid substrates. Based on this theory, we used ethyl acetate to dissolve the hydrophobic lipid substrate, then added aqueous buffer containing 0 – 0.1% Triton X-100 without drying off the ethyl acetate. This assay strategy worked well (see Table 2). However, the signal-to-background detection window for Triton X-100 working concentrations was limited. Under low Triton X-100 concentrations, the hydrophobic lipid substrate was not fully soluble and was not available to the NAPE-PLD enzyme,

-25-

therefore, the signal-to-background ratio was small. Increasing the concentration of Triton X-100 increased the availability of the substrate to the enzyme, resulted in higher signal-to-background ratio. However, further increasing Triton X-100 concentration resulted in much higher background fluorescence, thus reducing the signal-to-background ratio (Figure 5). Thus, for optimal substrate preparation conditions we selected condition 5 (Table 2).

Example 4

10

SUBSTRATE AND ENZYME TITRATION:

For substrate titration, as the substrate concentration was increased from 5 μM to 10 μM , the detection window was almost doubled while the background signal remained constant (Figure 6). A high concentration of enzyme (1:100) was used in order to find the maximum fluorescence signal under current buffer conditions (0.05% Triton X-100).

For enzyme titration, NAPE-PLD was serially diluted from 1:100 up to 1:6400 (Figure 7). The reaction was started by adding PED6 to a final concentration of 10 μM . The reaction volumes were 20 μl . The fluorescent intensity was measured every two minutes. Based on these results, 14 nM enzyme (1:1600) and a reaction time of 30 min were selected for the further experiments.

25

Example 5

K_m DETERMINATION FOR NAPE-PLD:

Values for K_m of 3.9 μM and V_{max} of 4.46×10^4 FU/min/ μg protein (Figure 8) were determined. The V_{max} value was normalized for the amount of protein used. In order to be able to identify inhibitors with different mode of actions, including competitive inhibitors, we chose to start the substrate titration from a concentration of

30

-26-

5 μM , a concentration close to the determined K_m value, and found 10 μM substrate concentration gave the best combination of signal to background ratio and sensitivity to inhibitor. Further, the following parameters for the NAPE-PLD assay conditions: 14 nM enzyme, 10 μM substrate with a reaction time of 30 minutes in a 20 μl volume.

5

Example 6

DMSO SENSITIVITY:

10

Since many chemical libraries are kept as stock solutions in DMSO, we tested the sensitivity of the assay to DMSO (Figure 9). The assay was somewhat sensitive to DMSO but DMSO was well tolerated.

15

Example 7

REPRESENTATIVE IC_{50} CURVES:

20

There are no known inhibitors of NAPE-PLD. Therefore, compounds that were found to inhibit NAPE-PLD during validation of the assay were used to demonstrate dose response activity in the assay (Figure 10). It is expected that a common "false positive" effect in the primary assay will be due to micelle-disrupting compounds, since the hydrophobic substrate is very dependent on the detergent in the buffer for solubility. When Triton X-100 is not present in the assay buffer, the substrate fluorescence is much lower, and this effect could mimic a positive compound. To identify such "false positives", one can measure fluorescence in the presence of compound and substrate, but in the absence of enzyme, to determine if compound interferes with the fluorescent intensity of the substrate in the presence of Triton X-100.

25
30

Example 8

PREPARATION OF Abh4 AND TESTING OF PED6 AS SUBSTRATE

Human Abh4 was cloned and expressed in FreeStyle 293F cells (Invitrogen), a
5 suspension cell line for transient expression, using the pcDNA3.1zeo_DEST vector.
The pcDNA3.1zeo_DEST is a modified vector of pcDNA3.2zeo (Invitrogen). The
pcDNA3.1zeo_DEST vector containing the Abh4 coding sequences is disclosed in
SEQ ID NO: 4. Abh4 was expressed with a C-terminal His tag (SEQ ID NO: 5). A
portion of the crude lysate was tested for hydrolysis of PED6 and resulting
10 fluorescence. Lysate (75 μ g protein) from transfected cells was added to a solution of
PED6 (5 μ M final assay concentration) in Tris HCl buffer (pH 7.6) containing 0.05%
Triton X-100 (to solubilize the substrate) in final volume of 100 μ L. The reaction in a
96-well black plate was monitored continuously in a fluorescence plate reader
Gemini, (SpectraMax), with excitation and reading from the top (excitation wavelength
15 488 nm, emission wavelength 520 nm). Lysate (75 μ g protein) of FreeStyle 293F
cells that had not been transfected was used as a control. Under these conditions, a
19-fold higher rate was observed with the lysate from transfected cells over the
control lysate, suggesting that the Abh4 present is efficiently hydrolyzing the
substrate PED6 (Figure 12). To further validate this finding, the inhibitor MAFP
20 (methylarachidonylfluorophosphonate) was used. At a concentration of 5.34 μ M, this
inhibitor showed >95% inhibition of the activity observed, consistent with the findings
of Simon and Cravatt (2006).

Thin layer chromatography (TLC) was performed to establish that the products
25 of hydrolysis of PED6 by Abh4 and by NAPE-PLD are different. TLC on silica gel
using chloroform:methanol:ammonia system of ethyl acetate-extracted enzymatic
reaction mixture showed that the reaction products are different.

-28-

What is claimed is:

1. A method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising:

- 5 a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles;
- b) adding an agent to at least one receptacle in the array of receptacles;
- c) adding a substrate to at least one receptacle in the array of receptacles wherein the substrate comprises a donor moiety and a quencher moiety
- 10 wherein intramolecular proximity of the donor moiety and the quencher moiety results in a quenched detectable signal;
- d) incubating the agent, the NAPE-PLD or Abh4 and the substrate in the array of receptacles for a predetermined period of time;
- e) measuring the amount of detectable signal from the donor moiety following
- 15 removal of the quencher moiety from the substrate by NAPE-PLD or Abh4 in the array of receptacles; and
- f) comparing the amount of detectable signal in a first receptacle comprising the agent, the substrate and the NAPE-PLD or Abh4 to the amount of
- 20 detectable signal in a second receptacle comprising the substrate and the NAPE-PLD or Abh4
- thereby identifying said agent as a modifying agent when the difference exceeds a predetermined threshold.

2. A method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising:

- 25 a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles;
- b) adding an agent to at least one receptacle in the array of receptacles;
- c) adding a substrate to at least one receptacle in the array of receptacles
- 30 wherein the substrate comprises a donor moiety and a quencher moiety wherein intramolecular proximity of the donor moiety and the quencher moiety results in a quenched detectable signal;

-29-

- d) measuring the amount of detectable signal from the donor moiety following removal of the quencher moiety from the substrate by NAPE-PLD or Abh4 in the array of receptacles at a first time point;
- e) incubating the agent, the NAPE-PLD or Abh4 and the substrate in the array of receptacles for a predetermined period of time;
- f) measuring the amount of detectable signal from the donor moiety following removal of the quencher moiety from the substrate by NAPE-PLD or Abh4 in the array of receptacles at a second time point; and
- g) comparing the amount of detectable signal at the first time point to the amount of detectable signal at the second time point,
- thereby identifying said agent as a modifying agent when the difference exceeds a predetermined threshold.

3. A method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising:
- a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles;
- b) adding an agent to at least one receptacle in the array of receptacles;
- c) adding a substrate to at least one receptacle in the array of receptacles wherein the substrate comprises a donor moiety and an acceptor moiety;
- d) incubating the agent, the NAPE-PLD or Abh4 and the substrate for a predetermined period of time;
- e) measuring the amount of detectable signal wherein the detectable signal measured is selected from the group consisting of the donor moiety, the acceptor moiety, the ratio of donor moiety to acceptor moiety and the donor-acceptor moiety complex; and
- f) comparing the amount of detectable signal in a first receptacle comprising the agent, the substrate and the NAPE-PLD or Abh4 to the amount of detectable signal in a second receptacle comprising the substrate and the NAPE-PLD or Abh4
- thereby identifying said agent as a modifying agent when the difference exceeds a predetermined threshold.

-30-

4. A method of identifying an agent that modifies the activity of NAPE-PLD or Abh4, the method comprising:
- a) adding NAPE-PLD or Abh4 to at least one receptacle in an array of receptacles;
 - 5 b) adding an agent to at least one receptacle in the array of receptacles;
 - c) adding a substrate to at least one receptacle in the array of receptacles wherein the substrate comprises a donor moiety and an acceptor moiety;
 - d) measuring the amount of detectable signal at a first time point wherein the detectable signal measured is selected from the group consisting of the
10 donor moiety, the acceptor moiety, the ratio of donor moiety to acceptor moiety and the donor-acceptor moiety complex;
 - e) incubating the agent, the NAPE-PLD or Abh4 and the substrate for a predetermined period of time;
 - f) measuring the amount of detectable signal at a second time point wherein
15 the detectable signal measured is selected from the group consisting of the donor moiety, the acceptor moiety, the ratio of donor moiety to acceptor moiety and the donor-acceptor moiety complex; and
 - g) comparing the amount of detectable signal at the first time point to the amount of detectable signal at the second time point
20 thereby identifying said agent as a modifying agent when the difference exceeds a predetermined threshold.
5. The method of claim 3 or 4 wherein the detectable signal is measured by
25 fluorescence resonance energy transfer.
6. The method of claim 1, 2, 3, or 4 further comprising incubation of the agent and the NAPE-PLD or Abh4 for a predetermined period of time before step c.
7. The method of claim 1, 2, 3 or 4 wherein steps a, b and c can be performed in any
30 order or can be performed together.
8. The method of claim 1, 2, 3 or 4 further comprising at least one control.

9. The method of claim 1, 2, 3 or 4 further comprising at least one inhibitor, inducer or modulator.
10. The method of claim 1, 2, 3 or 4 wherein the substrate is PED6.
- 5 11. The method of claim 10 wherein the PED6 is dissolved in ethyl acetate.
12. The method of claim 11 wherein the dissolved PED6 is added to a buffer comprising about 0.005 to 0.1 % Triton X-100.
- 10 13. The method of 12 wherein the buffer comprises about 0.05 % Triton X-100.
14. The method of claim 1, 2, 3 or 4 wherein the detectable signal is selected from the group consisting of a fluorochrome, chromophore, enzyme, linker moiety, biotin, electron donors, electron acceptors, dyes, metals, and radionuclide.
- 15 15. The method of claim 1 or 2 wherein the donor moiety and the quencher moiety are selected from the group consisting of BODIPY/DNP, Rhodamine/DNP and Cy dye/DNP.
- 20 16. The method of claim 3 or 4 wherein the donor moiety and the acceptor moiety are selected from the group consisting of Texas red and fluorescein, BODIPY and fluorescein, Europium and allophycocyanin (APC), cyan fluorescent protein/yellow fluorescent protein, and green fluorescent protein/blue fluorescent protein.
- 25 17. The method of claim 1, 2, 3 or 4 wherein the NAPE-PLD or Abh4 in step a is provided by culturing in the receptacle a prokaryotic or eukaryotic cell that is transiently or stably transfected to express the NAPE-PLD or Abh4.
- 30 18. The method of claim 1, 2, 3 or 4 wherein NAPE-PLD or Abh4 is provided following isolation from a biological sample or from cells transiently or stably transfected to express NAPE-PLD or Abh4.

-32-

19. The method of claim 18 wherein the biological sample is from a mammal selected from the group consisting of human, monkey, rat, mouse, rabbit, and guinea pig.

20. The method of claim 1, 2, 3 or 4 wherein one or more steps are performed by a robotic or workstation device.

21. An assay system for identifying an agent that modifies the activity of NAPE-PLD or Abh4, the assay system comprising:


- a) an array of receptacles;
- 10 b) NAPE-PLD or Abh4;
- c) a substrate comprising a donor moiety and a quencher moiety wherein the donor moiety is capable of detection; and
- d) at least one component wherein the component is selected from the group consisting of the agent(s), an inducer(s), an inhibitor, a modulator(s), a modulator(s) of the inducer(s), a modulator(s) of the inhibitor(s) and control(s).

22. An assay system for identifying an agent that modifies the activity of NAPE-PLD or Abh4, the assay system comprising:



- 20 a) an array of receptacles;
- b) NAPE-PLD or Abh4;
- c) a substrate comprising a donor moiety and an acceptor moiety wherein the donor moiety or the acceptor moiety or both are capable of detection; and
- d) at least one component wherein the component is selected from the group consisting of the agent(s), an inducer(s), an inhibitor, a modulator(s), a modulator(s) of the inducer(s), a modulator(s) of the inhibitor(s) and control(s).

23. A kit comprising at least one element of the assay system of claim 21 or claim 22 and instructions for use.

R, R'=long chain, saturated or partly unsaturated




N-acyl phosphatidylethanolamine (NAPE)



Phosphatidic acid

+



Anandamide

Figure 1

PED6: fluorescence from BODIPY group is internally quenched




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9





Figure 10

SEQ ID NO:1

ATGGATGAAAATGAAAGCAACCAGTCTCTGATGACAAGCAGCCAATATCCTAAAGAAGCAGTAAGA
 AAACGTCAAATTCAGCACGGAATTCGGGAGCAAGTGATTCCTTAGGTTTTCTAGGAAAAGCTTC
 AAACCTGGATTATAGACTAGAAGAAGATGTAACATAAATCCAAGAAAGGAAAAGATGGGAGATTTGTG
 AATCCGTGGCCAACATGGAAAAACCCCTCTATTCCAAATGTTCTCAGATGGCTGATAATGGAGAAA
 GATCACAGCAGTGTTCGAAGTTCTAAAGAGGAACTAGACAAAGAACTCCCAGTGCTTAAGCCATAT
 TTTATCACTAACCCCTGAAGAAGCTGGAGTGAGGGGAAGCTGGCTTAAGAGTCACATGGCTGGGACAT
 GCCACGGTAATGGTGGAAATGGATGAGCTCATATTTCTCACGGATCCCATCTTTAGCTCTCGTGCT
 TCACCATCGCAGTACATGGGTCCAAAGCGATTCGTCGTTCCCGTGACACAATAAGTGAACCTCCCT
 CCAATAGATGCGGTCCTTATCAGTCACAACCACTATGACCATCTGGACTACAATTCTGTCAATGCT
 TTGAATGAGCGATTTGGTAATGAGTTGAGATGGTTTGTGCCTTTGGGTCTCCTTGACTGGATGCAA
 AAATGTGGCTGTGAGAATGTGATTGAGTTGGACTGGTGGGAGGAGAATTGTGTCCCCGGACATGAT
 AAGTCACTTTTGTCTTTACACCTTCCCAGCACTGGTGTAAAAGGACTCTAATGGATGACAACAAG
 GTGCTATGGGGCAGCTGGTCTGTCTTGGGGCCTTGAATCGATTTTTTTTTCGCAGGAGATACTGGT
 TATTGCCCTGCTTTTGAAGAGATAGGAAAAAGATTTGGACCTTTTGACCTTGACGCTATTTCCCATC
 GGAGCTTATGAACCGAGGTGGTTTATGAAATACCAGCATGTAGACCCAGAAGAAGCTGTAAGGATT
 CACACTGATGTCCAAACAAGAAATCTATGGCAATTCACACTGGGGAACTTTTGCCTTAGCAAATGAG
 CATTACTTAGAGCCTCCAGTGAAGCTGAATGAAGCTCTAGAGAGATACGGACTTAACGCTGAAGAT
 TTTTTTGTCTTGAAGCATGGAGAATCAAGATACCTAAATAATGATGATGAAAACCTTTCATCACCAT
 CACCATCACTAA

SEQ ID NO:2

MDENESNQSL	MTSSQYPKEA	VRKRQNSARN	SGADSSRFS	RKSFKLDYRL	EEDVTKSKKG
KDGRFVNPWP	TWKNPSIPNV	LRWLIMEKDH	SSVPSKEEL	DKELPVLKPY	FITNPEEAGV
REAGLRVTWL	GHAATVMVEMD	ELIFLTDPIF	SSRASPSQYM	GPKRFRRSPC	TISELPPIDA
VLISHNHYDH	LDYNSVIALN	ERFGNELRWF	VPLGLLDWMQ	KCGCENVIEL	DWWEENCVPG
HDKVTFVFTP	SQHWCKRTL	DDNKVLWGSW	SVLGPWNRFF	FAGDTGYCPA	FEEIGKRFGP
FDLAAPIGA	YEPRWFMKYQ	HVDPEEAVRI	HTDVQTKKSM	AIHWGTFALA	NEHYLEPPVK
LNEALERYGL	NAEDFFVLKH	GESRYLNDD	ENFHHHHHH		

SEQ ID NO:3

DYRLEEDVTK	SKKGDGRFV	NPWPTWKNPS	IPNVLRWLIM	EKDHSSVPSS	KEELDKELPV
LKPYFITNPE	EAGVREAGLR	VTWLGHATVM	VEMDELIFLT	DPIFSSRASP	SQYMGPKRFR
RSPCTISELP	PIDAVLISHN	HYDHLDYNSV	IALNERFGNE	LRWFVPLGLL	DWMQKGCEN
VIELDWWEEN	CVPGHDKVTF	VFTPSQHWCK	RTLMDDNKVL	WGSWSVLGPW	NRFFFAGDTG
YCPAFEEIGK	RFGPFDLAAI	PIGAYEPRWF	MKYQHVDPEE	AVRIHTDVQT	KKSMAIHWGT
FALANEHYLE	PPVKLNEALE	RYGLNAEDFF	VLKHGESRYL	NNDDENFHHH	HHH

Figure 11

SEQ ID NO:5

MADDLEQQSQ GWLSSWLPTW RPTSMSQLKN VEARILOCLQ NKFLARYVSL PNQNKIWTVT
VSPEQND RTP LVMVHGFGGG VGLWILNMDS LSARRTLHTF DLLGFGRSSR PAFPRDPEGA
EDEFVTSIET WRETMGIPSM ILLGHSLGGF LATSYSIKYP DRVKHLILVD PWGFPLRPTN
PSEIRAPPAW VKAVASVLGR SNPLAVLRVA GPWGPGLVQR FRPDFKRKFA DFFEDDTISE
YIYHCNAQNP SGETAFKAMM ESFGWARREM LERIHILIRKD VPITMIYGSD TWIDTSTGKK
VKMQRPDSYV RDMEIKGASH HVYADQPHIF NAVVEEICDS VDHHHHHH

Figure 12




FIGURE 13

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/065028

A. CLASSIFICATION OF SUBJECT MATTER
INV. G01N33/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HENDRICKSON H STEWART ET AL: "Intramolecularly quenched BODIPY-labeled phospholipid analogs in phospholipase A2 and platelet-activating factor acetylhydrolase assays and in vivo fluorescence imaging" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC. NEW YORK, vol. 276, no. 1, 1 December 1999 (1999-12-01), pages 27-35, XP002186412 ISSN: 0003-2697 cited in the application abstract	1-23

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on the novelty claim(s) or which is cited to establish the public use of another invention or other special reason (as set forth in Article 17(2)(b) of the PCT Treaty)

O document referring to an oral disclosure, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 September 2008	26/09/2008

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Hinchliffe, Philippe
---	--